Back to Bigger Picture

BIGGER PICTURE Better care

An AI-designed lung drug reached patients. What did the trial find?

Rentosertib links two difficult searches: which biological target might change lung fibrosis, and what molecule could act on it? The AI-assisted answers reached a randomized trial in people with the disease.

AI-generated illustration: A candidate molecule moves from computational selection toward clinical testing.
A candidate molecule moves from computational selection toward clinical testing.AI-generated illustration of the idea, not a photograph of the actual people, equipment or event.
Trial size
71 people with pulmonary fibrosis
Treatment period
12 weeks
Highest-dose lung-function change
+98.4 mL versus −20.3 mL with placebo

How the idea works

  1. Choose a fibrosis target

    Models prioritise TNIK from disease-related biological evidence.

  2. Design an inhibitor

    Generative chemistry proposes a molecule to inhibit TNIK.

  3. Test against placebo

    Randomized dosing tests safety and lung-function signals in patients.

A disease that progressively stiffens the lungs

Idiopathic pulmonary fibrosis involves progressive scarring of lung tissue. The research programme used AI to prioritise TNIK, a protein involved in programmes linked to fibrosis and inflammation. A second design task produced a small molecule intended to inhibit that target.

Sources: [1]

Predictions still have to meet biology

The 2025 phase 2a study enrolled 71 patients in China. Participants were randomly assigned to three rentosertib regimens or placebo for twelve weeks, with patients and investigators blinded to allocation. The main outcome concerned adverse events; lung-function measures were secondary outcomes.

Sources: [1]

A change in the volume patients could exhale

In the highest-dose group, forced vital capacity increased by a mean 98.4 millilitres, versus a decline of 20.3 millilitres with placebo. This measure records how much air someone can forcefully exhale. The encouraging difference warrants a larger test; it does not establish longer survival or reversal of disease.

Sources: [1]

The important achievement is testability

Adverse events occurred in every group; liver toxicity and diarrhoea were among reasons for discontinuation. Small groups and short follow-up limit conclusions. What makes this case valuable is the complete chain from a machine-suggested biological hypothesis to a molecule and a controlled clinical experiment.

Sources: [1]

The original sources

  1. Nature MedicineA generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial

What to explore next

The promising antibiotic was hiding in a different medicine searchFinding a tiny survivor in millions of forest photographs
Explore all 99 applications